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Abstract CHEK2 gene is known as a tumor suppressor gene
in breast cancer (BC), which plays a role in DNA repair. The
germ line mutations in CEHK2 have been associated with
different types of cancer. The present study was aimed at
studying the association between CHEK2 mutations and
BC. Peripheral blood was collected from patients into a test
tube containing EDTA, and DNA was extracted from blood
samples. Then, we analyzed mutations including 1100delc,
IVS2+1>A, del5395bp, and I157T within CHEK2 gene in
patients with BC and 100 normal healthy controls according
to PCR-RFLP, allelic specific PCR, and multiplex-PCR.
Although IVS2+1G>A mutation within CHEK2 gene was
found in two BC patients, other defined mutants were not
detected. For the first time, we identified CHEK2 IVS2+
1G>A mutation, one out of four different CHEK2 alterations
in two Iranian BC patients (2%). Also, our results showed that
CHEK2 1100elC, del5395bp, and I157T mutations are not
associated with genetic susceptibility for BC among Iranian
population.
Keywords Breast cancer . CHEK2 .Mutation
Introduction
Breast cancer (BC) is the most common cancer in women.
According toWHO statistics, one out of every 8 to 10 women
will be diagnosed with BC. In Iran, the risk of BC is one out of
every 10 to 15 women with an onset age at least one decade
sooner than that observed in developed countries (Noori &
Tabarestani 2010). Considering the previous studies, mean
age of patients with BC in Iran is 48 years, compared to 55
in other countries (Dvarnia et al. 2012). The genetic factors
presumed to be involved in the development and increased
risks of BC have been demonstrated in several earlier studies.
In some cases, the inheritance of a mutated gene occurs. BC is
a severely heterogeneous disease caused by the interaction of
genetic and environmental factors, mostly in sporadic cases
(Keshavarzi et al. 2011). In some BC cases, the tumor sup-
pressor genes responsible for genome maintenance and DNA
repair show a high degree of genomic instability (Noori &
Tabarestani 2010).
Defective repair of DNA double-stranded breaks is associ-
ated with genetic susceptibility to BC (Noori & Tabarestani
2010; Kilpivaara et al. 2004). Ataxia Telangiectasia Mutated
(ATM) is a fragment of BRAC1-associated genome surveil-
lance complex (BASC) and is a primary repair-sensing mech-
anism. In response to double-strand break repair, checkpoint
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kinase 2 (CHEK2) is phosphorylated and spontaneously acti-
vated by ATM kinases. Later, activated CHEK2 monomers
are activated and phosphorylate a large number of substrates,
including tumor suppressor upstream gene P53, cell division
cycle (Cdc25) family, proteins of serine 988 BRCA1 genes,
and cell cycle control proteins (Strachan & Read 1996;
Meijers-Heijboer et al. 2002; Bayram et al. 2012). Thus,
CHEK2 as a tumor suppressor gene plays an important role
in DNA repair and maintenance of chromosomal stability
(Nevanlinna & Bartek 2006; Mohelnikova-Duchonova et al.
2010). The CHEK2 gene on chromosome 22q12.1 is prone to
mutate and produce cancer (Bayram et al. 2012; Nevanlinna&
Bartek 2006).
Despite many studies concerning the association between
mutations in CHEK2 gene and the risk of BC around the
world to clarify the mechanism of this association, further
large-scale in-depth studies still seem to be necessary
(Cybulski et al. 2007; Steven & Henry 2007).
In the present study, we focused on four CHEK2mutations
known to affect protein function (c.1100delC, del5395bp,
IVS2 + 1G > A, and I175T). The large CHEK2 deletion leads
to premature protein truncation at codon 381 (12). The
c.1100delC variant also leads to protein truncation at codon
381, making the mutant CHEK2 1100delC protein unstable
while abolishing the CHEK2 kinase activity (Cybulski et al.
2006a; Sodha et al. 2006). The splice site mutation (IVS2 +
1G >A) results in a 4-bp insertion due to an abnormal splicing
and creates an aberrantly spliced CHEK2 mRNA encoding a
truncated protein in exon3 and I157Tmissensemutation, lead-
ing to defective binding to BRCA1, Cdc25A, and p53
(Cybulski et al. 2006b; Bogdanova et al. 2005; Dong et al.
2003). The I157T product (I157T in fork head-associated
(FHA) domain of the gene) is a stable protein dimerized with
wild-type CHEK2, which is co-expressed in human cells.
Then, it disturbs the substrate binding and interferes with
wild-type CHEK2 in a dominant-negative manner (Bayram
et al. 2012; Bogdanova et al. 2005).
Due to lack of such study in Iranian women population, this
preliminary case-control study was conducted to examine the
frequencies of four CHEK2 mutations (c.1100delC,
del5395bp, IVS2 + 1G > A, and I157T) in BC patients and
healthy controls and also to investigate the role of these mu-
tations in susceptibility to BC among Iranian women.
Materials and method
In this study, we examined 100 women with BC for whom the
pathological data were confirmed by a pathologist. Other in-
formation including age (Table 1), staging (Fig. 1), grading
(Fig. 2), and histopathology results (Table 2) of cancer were
obtained from the medical records of previous survivors. Lack
of breast cancer in normal healthy controls was approved by
mammography. Five milliliters of peripheral blood was col-
lected from each BC patient and healthy control and was
transferred into a test tube containing EDTA. DNA was ex-
tracted from blood samples using a commercial DNA extrac-
tion kit (Qiagen, USA). The extracted DNA samples were
stored at −80 °C until use. This study was approved by the
local ethics committee of Hormozgan University of Medical
Sciences, Cellular and Molecular Research Center, Qazvin
University of Medical Sciences and Department of
Molecular Biology, Pasture Institute of Iran and written in-
formed consent were obtained from all patients and normal
controls.
Mutation analyses
All samples from BC patients and healthy controls were tested
for c.1100delC, del5395bp, IVS2 + 1G > A, and I157T mu-
tations. All reactions were performed using Veriti Thermal
Cycler ABI (Applied Biosystems, Foster City, CA, USA).
Analysis of CHK2 5395-bp deletion with multiplex-PCR
Multiplex-PCR was also performed for genotyping of large
deletion in exon 9 and 10 of CHEK2 gene, as described pre-
viously (Cybulski et al. 2007). Multiplex-PCR reaction was
performed using specific primers, including the first pair F: 5′-
TGTAAT GAG CTG AGATTG TGC -3′; R: 5′- CAG AAA
TGA GAC AGG AAG TT-3′ part breakpoint site in intron 8
and the second pair 5′- GTC TCA AAC TTG GCT GCG -3′;
5′- CTC TGT TGT GTA CAA GTG AC-3′ part breakpoint
site in intron 10. In mutation-negative cases, two PCR frag-
ments of 379 and 522 bp were amplified from the wild-type
allele. In mutation-positive cases, PCR product of 450 bp was
enlarged with the forward primer of the first pair and the
reverse primer of the second pair.
Optimal PCR conditions were as follows: a reaction vol-
ume of 25 μL containing 2.5 μL 10× buffer (Gen Fanavaran
Co), 0.8 μL dNTPs (10Mm),1.5 μLMgCl2 (50Mm), 0.3 Taq
DNA polymerase (unit/μl), 5 μL of each forward and reverse






Age (year) 48.29 ± 9.39 48.41 ± 8.01
Children number 3.37 ± 1.95 3.54 ± 1.70
Married status 96% 95%
Single status 4% 5%
Women with familial breast cancer 58% 32%
Women with sporadic breast cancer 42% 68%
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primers, 5 μL of DNA (20–50 ng/μl), and a remaining volume
(16.9 μL) of distilled water (DW). After an initial 10 min at
94 °C, DNAwas amplified by 29 cycles of 25 s at 94 °C, 40 s
at annealing temperature of 58 °C, and 45 s at 72 °C followed
by 1 cycle of 5 min at 72 °C. The presence of PCR products
was checked in each reaction by electrophoresis in 1.5% aga-
rose gel followed by visualization step by Gel Red™in gel
documentation systems shown in Fig. 1.
Analysis of CHK2 IVS2 + 1G > A and I157T mutations
with PCR-RFLP
CHEK2 IVS2 + 1G > A mutation was examined using PCR-
RFLP as explained previously (Bogdanova et al. 2005). A
genomic region including both the IVS2 + 1G > A and
I157T mutations in intron2 and exon3 of the CHEK2 gene
was amplified by PCR using mutagenic primers to allow the
restriction enzyme to examine the occurrence of these two
mutations.
The 194-bp fragment surrounds the G to A frame shift
mutation site in CHK2 IVS2 + 1G > A splice site in intron 2
and the T to C substitution mutation in CHK2 I157T site of
exon3. PCR was performed using specific primers F: 5′-
GCAAGAAACACTTTCGGATTTTCCGG -3′ and R: 5′-
CCACTGTGATCTTCTATGTCTGCA-3′. Optimal PCR
conditions were as follows: a reaction volume of 25 μL con-
taining 2.5μL 10X buffer (Gen Fanavaran Co), 0.8 μL dNTPs
(10 Mm), 1.5 μL MgCl2 (50 Mm), 0.3 Taq DNA polymerase
(unit/μl), 5 μL of each forward and reverse primers, 5 μL of
DNA (20-50 ng/μl), and a remaining volume (13.9 μL) of
distilled water (DW).
After an initial 5 min at 95 °C, DNA was amplified by
33 cycles of 45 s at 94 °C, 40 s at annealing temperature of
61.5 °C, and 45 s at 72 °C followed by 1 cycle of 5 min at
72 °C. PCR products were separately incubated for 16 h with
either ScrFI or PstI (New England Bio labs, Beverly, MA).
Restriction enzyme reaction products were separated on a 3%
agarose gel and visualized by gel red (Gel Red, UK) in a gel
documentation system.
To evaluate I157T mutation, the 194-bp product was
cleaved by PstI into two fragments of 20 and 170 bp, while
the normal product was not cleaved. In case of IVS211G > A
mutation, the normal product was cleaved by ScrFI and the
mutant PCR product was not cleaved. All positive cases were
confirmed by direct sequencing of PCR products using the
intronic primers 5′-CCTTCTTAGGCTATTTTCCTAC-3′
(forward) and 5′-AACCATATTCTGTAAGGACAGG-3′ (re-
verse). Sequencing was accomplished using the forward prim-
er and the sequences were assessed on Genetic Analyzer 3130
Fig. 2 a A normal DNA, B andH PCR product uncut with Pst1, C and K
heterozygous mutant-type cut with Scrf1: 194 bp and 174 bp fragmented
and E negative control (water) M DNA marker. b Heterozygous mutant-
type: 194 bp and 174 bp fragment by screening of PCR products using
restriction enzymes ScrfI and PstI;A1, heterozygous patient; B1,C, andD
homozygous normal
Fig. 1 Homozygous wild-type:
522-bp and 379-bp fragment; M
DNA marker 50 bp
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(Applied Biosystems, Hitachi, USA). The results of this assay
are shown in Fig. 2a, b.
Analysis of CHEK2 1100delC mutation with AS-PCR
Allele-specific PCR was performed to detect the 1100delC
mutation of CHK2 gene as described previously (Rashid
2005). Genotyping of CHEK2 mutation was executed using
allele-specific PCR amplification with primers CHEK2
(Jahani & Ghotbi 2002) ex10F:(5′-GCA AAA TTA AAT
GTC CTA ACT TGC-3′), CHEK2ex10R:(5′-GGC ATG
GTG GTGTGC ATC-3′) and CHEK2delC:(5′-TGG AGT
GCC CAA AAT CATA-3′). In mutation-negative cases, the
PCR product of 537 bp was enlarged from the wild-type allele
and PCR product of 200 bp was amplified in mutation-
positive cases.
Optimal PCR conditions were as follows: a reaction vol-
ume of 25 μL containing 2.5 μL 10× buffer (Gen Fanavaran
Co), 0.8 μL dNTPs (10 Mm), 1.5 μL MgCl2 (50 Mm), 0.2
Taq DNA polymerase (unit/μl), 0.5 μL of each forward and
reverse primer, 1 μL of DNA (20–50 ng/μL), and distilled
water (18 μL). After an initial 10 min at 94 °C, DNA was
amplified by 29 cycles of 25 s at 94 °C, 30 s at annealing
temperature of 52 °C, and 35 s at 72 °C followed by 1 cycle
of 5 min at 72 °C. PCR products were electrophoresed on
1.5% agarose gel containing 0.5 Gel red (Gel Red, UK) and
visualized in a gel documentation system (Gel Logic 212
PRO, USA), as illustrated in Fig. 3.
Table 2 Pathologic clinical
findings in 100 patients with
breast cancer
Breast cancer after age 45 Breast cancer before age 45
Variable
Tumor size <2 cm 29 60
Tumor size >2 cm 9 8
Frequency (%) P value Frequency (%) P value
Histopathology variables of BC patient
IDC 34 (%89.4) 0.56 39(%62.9) 0.63
NOS IDC 3 (%7.8) 0.13 20(%32.3) 0.60
ILC 1 (%2.6) 0.58 3(%4.8) 0.54
Grade
I 2(%5.3) 0.53 2(%3.2) 0.58
II 11(%28.9) 0.65 11(%17.7) 0.73
III 25(%65.8) 0.80 49(%79.30 0.88
Stage
Ia 6(%15.7) 0.87 9(%14.6) 0.87
Ib 0 0 2(%3.2) 0.50
IIa 17(%44.7) 0.87 33(%53.2) 0.93
IIb 9(%23.6) 0.30 4(%6.5) 0.35
IIIa 3(%7.8) 0.44 8(%12.9) 0.93
IIIb 1(%2.6) 0.69 2(%3.2) 0.63
IIIc 2(%5.2) 0.53 2(%3.2) 0.58
IVa 0 0 2(%3.2) 0.50
ER
+ 19(%50) 0.98 34(%54) 0.99
− 19(%50) 0.98 28(%46) 0.99
PR
+ 15(%39) 0.79 31(%50) 0.87
− 23(%61) 0.83 31(%50) 0.88
Ki67
+ 26(%68) 0.92 11(%17) 0.97
− 12(%32) 0.98 51(%83) 0.97
Her2/neu
+ 5(%13) 0.83 31(%50) 0.90
− 33(%87) 0.63 31(%50) 0.71
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Statistical analysis
The prevalence of three CHEK2 alleles in cases and controls
was assessed between variables using SPSS17.0 software and
EpiInfo 3.5.4 test. Odds ratios were generated from two-by-
two tables using EpiInfo 3.5.4. p ≤ 0.05 was considered as
significant. All mutations were within the anticipated alloca-
tion according to Hardy-Weinberg equilibrium in both groups.
Results
We examined the presence of four mutations in CHEK2 gene
in 100 breast cancer patients with a personal and/or family
history of breast cancer. The mean age of patients was
48.29 ± 9.39 years (range: 26–76). Controls were healthy
females with similar age range 48.41 ± 8.01 (range 26–80)
(Table 1). Among the patients, 96% were diagnosed with in-
vasive ductal carcinoma (IDC) from whom 73% were IDC,
23% IDC (NOS: not otherwise specified) and the rest with
invasive lobular carcinoma (ILC) (Table 2).
In total, 6% of patients were diagnosed with grade I, 56%
with grade II, 37% with grade III, and 1% with grade IV,
respectively (Fig. 4). The most common tumor stage was
IIA (Fig. 5 and Table 2).
Ninety-six percent of patients were married and 4% were
single (Table 1). Fifty-eight percent of patients had a family
history of breast cancer (Table 1). Thirty-eight percent of pa-
tients had an average age of less than 45 years (Table 1) and
10% had bilateral breast cancer (Table 4).
In total, 100 BC cases and 100 controls selected for our
study were successfully analyzed for 1100delC, IVS2 +
1G > A, I157T, and del5395bp mutations in CHEK2 gene
using AS-PCR, PCR-RFLP, andMultiplex-PCR, respectively.
Our observation showed a low frequency of IVS2 + 1G > A
mutation in two cases. The missense variant was present in
2% of the cases (p = 0.48) as presented in Table 3.
A positive case of CHEK2 mutation IVS2 + 1G > A was
associated with hereditary breast cancer and the other found to
have a sporadic nature (Table 4). None of the 100 analyzed
samples carried the CHEK2 1100delC, I157T, and del5395bp
mutations (Table 3). These results suggest that these mutations
are absent or perhaps present at a really low frequency among
Iranian population; nevertheless, we can verify the low risk
associated with frame shift variant of IVS2 + 1G > A.
Discussion
Forthe first time,we evaluated the incidence of CHEK2 muta-
tions in a case-control study of BC among Iranian women.
Unfortunately, only 30% of BC risk factors are known and
the additional causes of most cases are unknown (Dolan &
Glasser 2000). BRCA1 and BRCA2 susceptibility genes have
been identified in BC in previous studies (Miki et al. 1994;
Wooster et al. 1995). In addition, the genes CHEK2, ATM,
PALB2 (the partner and localizer of the BRCA2 gene)
BRIP (BRCA1-interactingprotein gene), and NCOA3
(Nuclear Receptor Coactivator 3) are considered as
Fig. 3 Homozygous wild-type: 537-bp fragment;M DNA marker 50 bp
and 100 bp
Fig. 4 Percentage of different
grades of tumor patients
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predisposing genes increasingthe risk of BC (Jahani & Ghotbi
2002). Therefore, we analyzed any CHEK2 mutation as well
asassociation between these mutations and breast cancer in
Iranian women.
Initially, we analyzed these mutations in an equal number
(100) of breast cancer and control cases. We found IVS2 +
1G > A missense variant in a positive case of CHEK2 muta-
tion IVS2 + 1G > A, which was associated with hereditary
breast cancer and the other that was found to have a sporadic
nature (2 out of 100 patients) (p = 0.48). By examining the
results of Hardy-Weinberg equilibrium using chi-square test,
our results have no statistically significant relationship (p = 0/
48) in our society.
We showed that this mutation was present with a very low
frequency in breast cancer patients and healthy controls of the
Iranian population. Similar results have reported that the
CHEK2 IVS2 + 1G > A variants are associated with BC risk
(Bogdanova et al. 2005; Consortium 2004). None of these 100
samples had CHEK2 1100delC (Sodha et al. 2006), I157T
(Strachan & Read 1996), and del5395bp mutations. Our re-
sults are similar to those reporting that there is no association
between CHEK2 1100delC (Rashid 2005; Ndawula et al.
2014), I157T (Kilpivaara et al. 2004; Bayram et al. 2012),
and del5395bp (Mohelnikova-Duchonova et al. 2010;
Cybulski et al. 2007) variations and breast cancer risk and
our cases were not selected based on family history.
CHK2 IVS2 + 1G > A mutation has a lower geographic
distribution (Cybulski et al. 2007; Bogdanova et al. 2005)
whereas the I157T mutation shows a higher geographic dis-
tribution (Cybulski et al. 2004a; Cybulski et al. 2004b). This
variant has been reported in ethnically diverse populations and
is associated with a modest risk for developing BC among
German and Belarusian populations (Bogdanova et al.
2005). Also, the protein-truncating variant IVS2 + 1G > A
mutation is detected in Slavic populations of Eastern
Europe, German, and Byelorussian populations (Cybulski
et al. 2007; Bogdanova et al. 2007)as well as Polish cancer
patients (Cybulski et al. 2004b).
There are only few studies in some countries investigating
the possible relationship between IVS2 + 1G > A CHEK2
gene mutation and an increased risk of breast cancer
(Bogdanova et al. 2005). It should be noted that the rare oc-
currence of IVS2 + 1G > A mutation may be related to lack of
sufficient studies reported from different geographical regions
(Einarsdóttir et al. 2006).
Fig. 5 Frequency of different
stages of tumor patients
Table 3 Frequency of the CHEK2 mutations in Iranian population
Mutation Case(No = 100) Control(No = 100) P value
Yes No Yes No
With IVS2 + 1G > A 2 98 0 100 0.48
With I157T 0 100 0 100 0
With 5395 bp 0 100 0 100 0
With 1100delC 0 100 0 100 0
Table 4 The relationship between IVS2 + 1G > A mutation and clinic
pathology parameter of breast cancer
Characteristic Overall Present Absent P value
>45 62(62%) 2(3.2%) 60(97.3%) 1.00
≤45 38(38%) 0 38(100%)
Familial breast cancer 58(58%) 1(1.4%) 57(98.5%) 0.25
Unselected breast cancer 42(42%) 1(1.4%) 41(98.5%))
Bilateral breast cancer 10(10%) 0 10(100%)
Histological type
IDC 73(74%) 1(1.5%) 72(98.5%) 0.6
IDC (NOS) 23(23%) 1(4%) 22(95.6%)
ILC 4(3%) 0 4(100%)
Stage
1A 16(16%) 1(6.2%) 15(93.7%) 0.1
2A 52(52%) 1(1.9%) 51(98%)
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These results confirm the geographical and ethnic differ-
ences between populations and the need for further investiga-
tions in different nations.
Although it is widely accepted that the risk of BC may
be higher for women who have both a CHEK2 gene muta-
tion and a family history of BC (Cybulski et al. 2011), our
results fail to clearly demonstrate a role for CHEK2 muta-
tion IVS2 + 1G > A in inherited susceptibility to breast
cancer similar to other studies (Bogdanova et al. 2005;
Liu et al., 2012).This may be explained by an interaction
of CHEK2 mutations with susceptibility alleles in other
genes to increase the inherited BC prevalence (Kilpivaara
et al. 2004; Consortium 2004).
The I157T mutation has not been identified in differ-
ent populations (Consortium 2004; Einarsdóttir et al.
2006). Moreover, no increased risk of breast cancer
due to I157T CHEK2 gene mutation was observed in
Moroccan population (ElAmrani et al. 2014). I157T had
a lower incidence in some countries when compared to
1100delC mutation in patients with breast cancer
(Consortium 2004; Meijers-Heijboer et al. 2003).
We did not find the 1100delC mutation in Iranian popula-
tion, which is in line with previous studies and led us to pro-
pose that the c.1100delC may not contribute to BC suscepti-
bility in Asian (Choi et al. 2008; Song et al. 2006; Bell et al.
2007; Lee & Ang 2008; Rajkumar et al. 2003) countries and
North America (González-Hormazábal et al. 2008), compared
to the pattern observed in Northern and Eastern European
countries (ElAmrani et al., 2014). On the other hand, these
countries have a traditionally common origin compared to
other countries.
These findings are in agreement with the hypothesis that
the existence of a c.1100delC frequency gradient from these
regions is caused by an ancestrally common origin in the
North (ElAmrani et al., 2014). This gradient may be more
accentuated in the Middle East countries, which may explain
the absence of this mutation among Iranian population.
CHEK2 del5395bp gene mutation increases the risk of
breast cancer in some countries (Cybulski et al., 2007; Bąk
et al., 2014).
Both protein-truncating mutations (CHK2 1100delC,
I157T, and IVS2 + 1G > A) are reported to be associated with
breast, prostate, thyroid, kidney, and bladder cancer (Cybulski
et al., 2004b). In contrast, several studies have shown no as-
sociation between these mutations and susceptibility to cancer
(González-Hormazábal et al., 2008; Osorio et al., 2004).
Interestingly, two different investigators have reported that
the CHEK2 I157Tmutation seems to be protective against
lung cancer in patients from Eastern Europe (Cybulski et al.,
2008).
Obviously, a similar type of study with a higher number of
samples could be useful to show the possible increase in fre-
quency of CHEK2 mutation and may lead to faster diagnosis
of patients with breast cancer. On the basis of results obtained
from different countries with bigger samples, the association
between increased risk of breast cancer and CHEK2 gene
mutation has been confirmed.
Several reasons could explain this situation. Firstly, the
number of individuals recruited in this study was comparative-
ly small and some relations may have been missed as a result
of limited study. Secondly, it was a hospital-based investiga-
tion and the study populations were selected from a single
organization (Tehran University, Milad Hospital); therefore,
the selection bias was inevitable, and the participants may
not have presented the common ethnic characteristics of the
whole Iranian society. Thirdly, the sample size used in our
study was preferred according to several previous stud-
ies (ElAmrani et al. 2014; Meijers-Heijboer et al. 2003;
Choi et al. 2008; Song et al. 2006; Bell et al. 2007; Lee
& Ang 2008; Rajkumar et al. 2003; González-
Hormazábal et al. 2008; Bąk et al. 2014; Osorio et al.
2004; Cybulski et al. 2008; Iniesta et al. 2010), and it is
therefore essential for our current findings to be con-
firmed in a larger independent study. Fourthly, the pres-
ent study only focused on a single gene with no con-
siderations on gene-environment and gene-gene interac-
tions, which can influence the characteristic susceptibil-
ity to BC.
In conclusion, for the first time, we identified one out of
four different CHEK2 alterations in two patients (2%) and the
occurrence of 1100delC, I157T, and del5395bp mutations in
CHEK2 gene, which are usually absent or are present at really
low frequency in breast cancer patients and healthy controls of
the Iranian population.
As a result, we concluded that it is not a suitable predictive
test for other CHEK2 mutations in a clinical setting for breast
cancer among Iranian population. On the other hand, further
studies examining the total coding sequence of CHEK2 must
be performed. Our study reveals this relationship, and al-
though the number of patients was low, the patients and con-
trols were fully age-matched.
Moreover, many large-scale studies are needed to confirm
our results, particularly in patients with different ethnic origins
for better understanding of CHEK2 1100delC, IVS2 +
1G > A, del5395bp, and I157T mutations and susceptibility
to breast cancer. However, the overall number of detected
variants in our study was relatively small, and a number
of associations may have been missed as a result of
limited study scale. The authors suggest further studies
regarding the gene-gene interaction between CHEK2
gene and other tumor suppressor genes to demonstrate
the cancer risk in Iranian women. Finally, in agreement
with previous studies, except for IVS2 + 1G > A mu-
tation (which is usually observed rarely), the other three
CHEK2 mutations do not play an important role in the
breast cancer risk in Iran
Comp Clin Pathol
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